Last reviewed · How we verify
multimodal:acetaminophen, gabapentin, ketamine, bupivacaine
This multimodal formulation combines four analgesic and anesthetic agents with distinct mechanisms to provide synergistic pain relief through multiple pathways.
This multimodal formulation combines four analgesic and anesthetic agents with distinct mechanisms to provide synergistic pain relief through multiple pathways. Used for Acute and chronic pain management, Postoperative pain.
At a glance
| Generic name | multimodal:acetaminophen, gabapentin, ketamine, bupivacaine |
|---|---|
| Sponsor | University of Wisconsin, Madison |
| Drug class | Multimodal analgesic combination |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Acetaminophen inhibits prostaglandin synthesis; gabapentin modulates calcium channels and reduces neuronal excitability; ketamine antagonizes NMDA receptors to block pain signaling; and bupivacaine is a local anesthetic that blocks sodium channels. Together, these agents target pain through peripheral, spinal, and central mechanisms, allowing lower individual doses and potentially reducing adverse effects.
Approved indications
- Acute and chronic pain management
- Postoperative pain
Common side effects
- Dizziness
- Sedation
- Nausea
- Local injection site reactions
Key clinical trials
- ACL Repair and Multimodal Analgesia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: